Analbuminemia is an extremely rare congenital disease that denotes very low circulating levels of albumin (<1.0 g/L) [1] [2]. As one of the main plasma proteins, involved in oncotic pressure regulation and in the transport of numerous compounds throughout the body, albumin is a highly important molecule for human body functioning [1] [3]. However, virtually all patients develop only minimal symptoms as significant levels of lipoproteins (but also other classes of proteins) are secreted to compensate for albumin loss [1] [4]. Excessive hypercholesterolemia predisposes patients suffering from this rare condition to atherosclerosis and cardiovascular diseases [1] [4]. The main manifestations of analbuminemia are mild fatigue, edema around the ankles, and hypotension [1] [2]. Notable complications that have been described are osteoporosis, development of hypercoagulable disorders, infections of the respiratory tract, intrauterine growth retardation, and fetal death [5]. In fact, some authors claim that the very few cases of analbuminemia described in the literature are due to the underdiagnosis related to very early deaths from this condition [4].

The very rare occurrence of analbuminemia (only 50 cases have been reported in the literature and an incidence rate of < 1 in 1 million individuals was established) and the nonspecific, generally benign symptomatology must not mislead the physician from taking a detailed patient history and conducting a thorough physical examination [1]. A presumptive diagnosis can be made after laboratory studies that confirm profoundly low levels (< 1.0 g/L) of albumin in the serum but with normal liver function (coagulation panel and serum transaminases within physiological limits) and exclusion of albumin loss through the kidneys or the gastrointestinal tract [1] [2] [4] [6] [7]. Since certain molecules are usually bound to albumin at the time of testing (such as calcium and thyroxine), a true diagnosis may be delayed or missed for a significant period of time because of misleading laboratory results [1] [4] [8]. For this reason, more advanced studies, including molecular analysis to detect gene mutations located on chromosome 4, are necessary to solidify the diagnosis [1] [2] [9]. Because the disorder is transferred through an autosomal recessive pattern of inheritance [1] [2] [7], a family history might provide important clues as well, making it a vital constituent of the diagnostic workup.

There is no specific cure for analbuminemia, but treatment focuses on managing symptoms and preventing complications. This may include dietary modifications to manage lipid levels, diuretics to reduce edema, and in some cases, albumin infusions. Regular monitoring by healthcare professionals is essential to adjust treatment plans as needed.

The prognosis for individuals with analbuminemia varies. Many people can lead relatively normal lives with appropriate management of symptoms. However, the condition can lead to complications such as cardiovascular issues due to hyperlipidemia. Early diagnosis and tailored treatment plans can significantly improve quality of life and outcomes.

Analbuminemia is caused by mutations in the albumin gene, which is responsible for the production of albumin. These genetic mutations are inherited in an autosomal recessive pattern, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to develop the condition.

Analbuminemia is extremely rare, with only a few cases reported worldwide. Its rarity makes it challenging to determine precise prevalence rates. The condition affects both males and females equally and has been identified in various ethnic groups.

The absence or severe deficiency of albumin in analbuminemia disrupts the body's fluid balance, leading to the accumulation of fluid in tissues (edema). Albumin also plays a role in transporting hormones, vitamins, and drugs, so its deficiency can affect these processes. Additionally, the liver may compensate by producing more lipoproteins, leading to hyperlipidemia.

As a genetic disorder, analbuminemia cannot be prevented. However, genetic counseling may be beneficial for families with a history of the condition. This can help at-risk individuals understand their chances of passing the condition to their offspring and explore reproductive options.

Analbuminemia is a rare genetic disorder characterized by the absence or low levels of albumin in the blood. It presents with symptoms like edema and hyperlipidemia, and while there is no cure, symptoms can be managed with appropriate treatment. Understanding its genetic basis and pathophysiology is crucial for diagnosis and management.

For patients diagnosed with analbuminemia, understanding the condition is key to managing it effectively. While it is a lifelong condition, many people can lead normal lives with proper care. Regular check-ups, a balanced diet, and adherence to treatment plans are important. Patients should work closely with their healthcare providers to monitor their health and adjust treatments as necessary.

1. Del Ben M, Angelico F, Loffredo L, Violi F. Treatment of a patient with congenital analbuminemia with atorvastatin and albumin infusion. World J Clin Cases. 2013;1(1):44-48.
2. Campagna F, Fioretti F, Burattin M, et al. Congenital analbuminemia attributable to compound heterozygosity for novel mutations in the albumin gene. Clin Chem. 2005;51:1256–1258.
3. Boldt J. Use of albumin: an update. Br J Anaesth. 2010;104:276–284.
4. Dagnino M, Caridi G, Haenni U, et al. Molecular Diagnosis of Analbuminemia: A New Case Caused by a Nonsense Mutation in the Albumin Gene. Int J Mol Sci. 2011;12(11):7314-7322.
5. Wilkins TA, Midgley JE, Barron N. Comprehensive study of a thyroxin-analog-based assay for free thyroxin (“Amerlex FT4”). Clin Chem 1985;31:1644-1653.
6. Lyon AW, Meinert P, Bruce GA, Laxda VA, Salkie ML. Influence of methodology on the detection and diagnosis of congenital analbuminemia. Clin Chem. 1998;44:2365-2367
7. Koot BG, Houwen R, Pot DJ, Nauta J. Congenital analbuminaemia: biochemical and clinical implications. A case report and literature review. Eur J Pediatr. 2004;163:664-667
8. Stockigt JR, Stevens V, White EL, Barlow JW. “Unbound analog” radioimmunoassays for free thyroxin measure the albumin-bound fraction. Clin Chem 1983;29:1408-1410
9. Minghetti PP, Ruffner DE, Kuang WJ, et al. Molecular structure of the human albumin gene is revealed by nucleotide sequence within q11-22 of chromosome 4. J Biol Chem. 1986;261:6747–6757.